Beijing Leadman Biochemistry Co.,Ltd. (SHE:300289)
5.88
0.00 (0.00%)
Sep 4, 2026, 3:04 PM CST
SHE:300289 Revenue
Beijing Leadman Biochemistry had revenue of 81.50M CNY in the quarter ending June 30, 2026, a decrease of -0.09%. This brings the company's revenue in the last twelve months to 317.79M, down -7.18% year-over-year. In the year 2025, Beijing Leadman Biochemistry had annual revenue of 326.31M, down -11.86%.
Revenue (ttm)
317.79M
Revenue Growth
-7.18%
P/S Ratio
10.07
Revenue / Employee
756.63K
Employees
420
Market Cap
3.20B
| Fiscal Year End | Revenue | Change | Growth |
|---|---|---|---|
| Dec 31, 2025 | 326.31M | -43.92M | -11.86% |
| Dec 31, 2024 | 370.23M | -91.33M | -19.79% |
| Dec 31, 2023 | 461.55M | -244.42M | -34.62% |
| Jan 1, 2023 | 705.98M | 141.92M | 25.16% |
| Jan 1, 2022 | 564.06M | 92.55M | 19.63% |
| Dec 31, 2020 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2019 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2018 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2017 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
| Dec 31, 2016 | Upgrade Pro | Upgrade Pro | Upgrade Pro |
Revenue Definition
Revenue, also called sales, is the amount of money a company receives from its business activities, such as sales of products or services. Revenue does not take any expenses into account and is therefore different from profits.
Related Stocks
| Company Name | Revenue |
|---|---|
| Shanghai Kehua Bio-Engineering Co.,Ltd | 1.69B |
| Ningbo David Medical Device | 584.68M |
| Chison Medical Technologies | 441.10M |
| Medprin Regenerative Medical Technologies | 400.85M |
| Tellgen | 392.11M |
| Nanjing Medlander Medical Technology | 383.30M |
| Shanghai General Healthy Information and Technology | 371.61M |
| CareRay Digital Medical Technology | 319.79M |